G&A at other companies
Segments
By segment
See fullOther financials
Where this comes from
Reported directly by Apogee Therapeutics, Inc. in its filing.
Tagged under the XBRL concept us-gaap:GeneralAndAdministrativeExpense.
The official record: Apogee Therapeutics, Inc.’s 10-Q, filed May 11, 2026, on SEC EDGAR. View the filing →
Ask your AI about Apogee Therapeutics, Inc.'s g&a.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Apogee Therapeutics, Inc.'s G&A?
- Apogee Therapeutics, Inc. (APGE) reported G&A of $21.95M in Q1 2026.
- How has Apogee Therapeutics, Inc.'s G&A changed year-over-year?
- Apogee Therapeutics, Inc.'s G&A increased by 31.4% year-over-year, from $16.71M to $21.95M.
- What is the long-term trend for Apogee Therapeutics, Inc.'s G&A?
- Over 2 years (2023 to 2025), Apogee Therapeutics, Inc.'s G&A has grown at a 69.8% compound annual growth rate (CAGR), from $24.58M to $70.88M.
- What does G&A mean?
- Overhead costs not directly tied to production or sales — corporate management, legal, accounting, office rent, insurance, and other administrative functions.